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Summary
Among the factors modulating transplant rejection,
chemokines and their respective receptors deserve special
attention. Increased expression of monocyte chemo-
attractant protein-1 (MCP-1) and its corresponding recep-
tor (chemokine receptor-2, CCR2) has been implicated in
renal transplant rejection. To determine the impact of the
MCP-1-2518G and CCR2-64I genotypes on renal allo-
graft function, 167 Korean patients who underwent trans-
plantation over a 25-year period were evaluated. Genomic
DNA was genotyped using polymerase chain reaction
followed by restriction fragment length polymorphism
analysis. Fifty-ﬁve (32.9%) patients were homozygous for
the MCP-1-2518G polymorphism. Nine (5.4%) patients
were homozygous for the CCR2-64I polymorphism. None
of the investigated polymorphism showed a signiﬁcant
shift in long-term allograft survival. However, a signiﬁcant
increase was noted for the risk of late acute rejection in
recipients who were homozygous for the MCP-1-2518G
polymorphism (OR, 2.600; 95% CI, 1.125–6.012; P =
0.022). There was also an association between the MCP-
1-2518G/G genotype and the number of late acute rejec-
tion episodes (P = 0.024). Although there was no difference
in the incidence of rejection among recipients stratiﬁed by
the CCR2-V64I genotype, recipients with the CCR2-V64I
GG genotype in combination with the MCP-1-2518G/G
genotype had a signiﬁcantly higher risk of acute or late
acute rejection among the receptor-ligand combinations
(P = 0.006, P = 0.008, respectively). The MCP-1 variant
may be a marker for risk of late acute rejection in Korean
patients.
Introduction
Despite advances in immunosuppression and the overall
medical care of renal transplant recipients, which have led
to an improvement in allograft survival, chronic renal
allograft rejection continues to be a major impediment to
successful organ transplantation (Milford, 1994). Acute
rejection is the single most important risk factor for devel-
oping chronic renal allograft rejection (Kamoun, 2001;
Ramanathan  et al., 2001). Donor-recipient HLA mis-
matches, recipient race, donor age and delayed graft func-
tion have been shown to be associated with rejection
episodes (Chertow et al., 1996). Genetic polymorphisms,
other than those at the HLA locus, are attractive factors
that might explain some of the clinical heterogeneity
with regard to outcome of organ transplantation. Genetic
variation may inﬂuence the function or expression of key
immunoregulatory molecules that mediate transplant
rejection.
During acute allograft rejection, monocytes and T-
effector cells are directed into the transplant and produce
a characteristic tubular or vascular inﬁltrate (Lalor &
Adams, 2001). The complex process of extravasation and
inﬂux of leukocyte subsets into the site of tissue injury
appears to be mediated, to a signiﬁcant extent, by the
expression of speciﬁc chemokines and chemokine receptors
(Nelson & Krensky, 2001). Speciﬁcally, the expression of
the CC-chemokine MCP-1 together with the corresponding
chemokine receptor CCR2 can be detected in mononuclear
cells inﬁltrating the kidney graft (Nadeau et al., 1995;
Pavlakis et al., 1996; Grandaliano et al., 1997; Nagano
et al., 1997; Robertson et al., 2000; Segerer et al., 2001).
Rovin  et al. (1999) ﬁrst reported that the MCP-1-
2518A/G polymorphism demonstrates ethnic heterogeneity
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in the general population. The G allele frequency is
increased in Asian and Mexican populations compared to
European American and African American populations.
Kim et al. (2002) reported that the A allele, at –2518 of
the MCP-1 gene, was associated with the up-regulation of
MCP-1, which might result in a more severe proteinuria
in Korean patients with lupus nephritis. Krüger et al.
(2002) reported that the G allele at MCP-1-2518 increased
MCP-1 production in immunosuppressed transplant
recipients and was a risk factor for kidney allograft failure
in patients who underwent kidney transplantation at two
centres, one in Germany and one in the United States.
These discrepancies may have been caused by differences
in the diseases or by ethnic heterogeneity. Although there
is to date no evidence that the CCR2-64I polymorphism
alters CCR2 expression or function of leukocytes, Abdi
et al. (2002) reported that signiﬁcant reductions in risk of
acute renal transplant rejection were found in recipients
who had the CCR2-64I allele and underwent kidney
transplantation in the United States. Therefore, in this
study, we investigated whether MCP-1-2518 and CCR2-
64I variants are associated with altered kidney allograft
outcome in Korean patients.
Materials and methods
Patient demographics
A total of 167 ﬁrst renal allograft recipients transplanted
at two centres in Korea (Kyung Hee University Medical
Center, Seoul and Busan Baik Hospital, Busan) from 1979
to 2005 were analysed. Demographic data for donor and
recipient age and gender, HLA-mismatch, serum creati-
nine of donor, immunosuppressive therapy, presence of
rejection episodes and graft survival were extracted from
the hospital record. Acute rejection was determined
by allograft biopsy in about 35% of renal transplant
rejections. The remaining was deﬁned by an increase
in creatinine level by 30% from baseline that was not
attributable to other causes with subsequent return to
baseline after antirejection therapy. Late acute rejection
was deﬁned by the development of acute rejection six
months post-transplant. Graft survival was deﬁned as
recipient survival with a functioning renal transplant.
The Institutional Review Board approved the study, and
written informed consent was obtained at the time of
enrolment.
Determination of genotypes
Blood samples for genomic DNA were collected before
2004. Polymerase chain reaction and restriction fragment
length polymorphism (PCR-RFLP) study was performed
to detect genotypes from the DNA sequence variants of
the MCP-1-2518 and CCR2-64I polymorphisms. Genomic
DNA was prepared from heparinized venous blood using
a Core-one™ blood genomic DNA isolation kit (Core-
biosystem, Seoul, Korea). PCR-RFLP was performed as
described by Rovin et al. (1999) for MCP-1 genotyping.
The forward primer was 5′-CCGAGATGTTCCCAG-
CACAG-3′, and the reverse primer was 5′-TGCTTT-
GCTTGTGCCTCTT-3′. A total of 20 μL of the reaction
mixture contained 200 ng of genomic DNA, 10 pmol of
each primer, 200 μm of each dNTP and buffers recom-
mended by the manufacturer. A 930-bp segment of the
MCP-5′-ﬂanking region between nucleotide –1817
and –2746, relative to the major transcriptional start site
deﬁned by Ueda et al. (1994), was ampliﬁed by GeneAmp
PCR system 9600 (Applied Biosystems, Foster City, CA,
USA) under the following conditions: 35 cycles of 30 s at
94 ºC, 30 s at 64 ºC and 30 s at 72 ºC. The extension
time of the last cycle was set at 7 min. PCR products were
digested by the corresponding restriction enzyme Pvu II
(Takara Shuzo Co, Kyoto, Japan) for 16  h at 37  ºC.
Digestive products were separated from 1% agarose gels
stained with ethidium bromide. Pvu II digested the 930-bp
DNA segment from G/G homozygous individuals into
708- and 222-bp fragments. DNA from A/A homozygous
individuals was not cut with Pvu II. DNA from A/G
heterozygous individuals showed the expected fragments
at 930, 708 and 222 bp.
CCR2-V64I genotyping was performed as originally
described by Smith et al. (1997) with some minor modiﬁ-
cations. PCR was performed as described previously
except for the use of an annealing temperature of 57 °C.
The forward primer was 5′-ATTTCCCCAGTACATC-
CACAAC-3′, and the reverse primer was 5′-CCCACAAT-
GGGAGAGTAATAAG-3′. PCR cycles were as follows:
95 °C for 3 min followed by 35 cycles each of 95 °C for
30 s, 57 °C for 30 s and 72 °C for 30 s. Ampliﬁcation
resulted in a 317-bp product, 10 μL of which was then
digested in a 20-μL reaction for 16 h with 1 unit of Fok I
(New England BioLabs, Beverly, MA, USA) per the manu-
facturer’s recommendations. An A at nucleotide position
190 encodes isoleucine at amino acid position 64 and
yields restriction fragments of 197 and 120 bp after Fok I
digestion. By contrast, the 317-bp amplicon remains uncut
if a G encoding a valine is present.
MCP-1 production
MCP-1 released from unstimulated and stimulated peripheral
blood mononuclear cells (PBMC) was determined by
enzyme-linked immunosorbent assay (ELISA) as described
previously (Rovin et al., 1999). Brieﬂy, PBMC from kidney
transplant recipients, a total of 22 patients (A/A 6, A/G 9,
G/G 7), were isolated by density gradient centrifugation.
PBMCs were cultured for 24 h with and without addition
of 10 ng mL
–1 IL-1 (R & D Systems, Minneapolis, MN,
USA). MCP-1 concentrations were assayed in cell-free
supernatants by speciﬁc ELISA according to the manufac-
turer’s instructions (Quantikine; R & D Systems).
Statistical analyses
Patient genotypes were used as categorical independent
variables for analyzing continuous outcome variables
(graft survival), the binary variable (presence or absenceRisk of late acute rejection at MCP-1-2518GG 27
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of a rejection episode) and the ordinal variable (number of
acute rejection episodes). Nominal logistic ﬁt was used to
assess the association of genotypes with the incidence of
acute rejection. anova was used when the effect of two
independent variables (factors) on a dependent numerical
variable was examined. Graft survival was analysed with
Kaplan-Meier estimates. Groups were compared with the
log rank test. Multivariate analysis for the respective risk
factors of acute rejection or graft survival was performed
with logistic regression or Cox regression. Fisher’s exact
test was used to test for differences in immunosuppressive
therapy between the groups. A P < 0.05 was considered
signiﬁcant. The statistical software package (sas 9.1 for
Windows) was used for the calculations.
Results
Patient demographic and clinical data
The genotype frequencies of MCP-1-2518A/G and CCR2-
V64I polymorphisms were as follows. For the MCP-1-2518
genotypes among the 167 kidney transplanted patients,
21 had the A/A genotype (12%), 91 the A/G type (55%)
and 55 the G/G type (33%). We could get only 166 PCR
products for CCR2 and the remaining one was not ampli-
ﬁed; then, we genotyped only 166 patients for CCR2. For
the CCR2-V64I genotypes, among the 166 kidney trans-
planted patients, 9 had the A/A genotype (5%), 84 the
G/A type (51%) and 73 the G/G (44%). The overall inci-
dences of acute rejection and late acute rejection were
31.7% and 16.2%, respectively. Total number of acute
rejection episodes was 85. Biopsy was carried out in 30 of
85 episodes, and 26 cases (87%) among the biopsy pro-
cedures were conﬁrmed as acute rejection. Individuals
with or without the MCP-1-2518G/G genotype did not
differ with respect to other risk factors for rejection
frequency and allograft failure such as donor age, ethnic
background, living donor, HLA-mismatch, immuno-
suppressive therapy, recipient age and gender and the serum
creatinine level of the donor. However, individuals with
the MCP-1-2518G/G genotype had a higher occurrence
of late acute rejection than individuals with other geno-
types (Table 1).
Univariate analysis and multivariate analysis of risk 
factors for late acute rejection
The univariate analysis of variables related to the occur-
rence of late acute rejection is shown in Table 2a. The
variables related to the occurrence of late acute rejection
were recipient age, donor age, number of HLA-mismatch,
donor serum creatinine level and MCP-1-2518 GG
genotype (respective P values are shown in Table  2a).
Total numbers of patients with and without late acute
rejection episodes were 27 and 140, respectively.
To verify the results of the univariate analysis, a
multivariate logistic regression analysis using the variables
found signiﬁcant in the univariate analysis was performed.
The multivariate logistic regression analysis revealed that
only the presence of the G/G genotype was associated
with the occurrence of late acute rejection (Table 2b).
Association of the polymorphism with acute or late acute 
rejection
The relationship of the patients’ MCP-1-2518 or CCR2-
V64I genotypes with the incidence of renal allograft
rejection was analysed. The percentage of recipients who
had a late acute rejection episode was more than twofold
higher in individuals with a MCP-1-2518G/G genotype
vs. A/A or A/G genotypes (25.5% for GG vs. 11.6% for
AA or AG; odds ratio [OR], 2.60; 95% CI, 1.13–6.01;
P = 0.022). There was no difference in the incidence of
rejection among recipients stratiﬁed by the presence or
absence of the CCR2-64I allele (P = 0.334). There was
also a correlation between the MCP-1-2518 GG genotype
and the number of late acute rejection episodes (P = 0.024)
(Table 3).
To explore whether consequences of genetically deter-
mined alterations of receptor–ligand interactions in
the chemokine system would better identify high-risk
recipients, further analysis of combinations of these
Table 1. Demographic and clinical data for 167 kidney transplanted patients with or without the MCP-1-2518G/G genotype
MCP-1-2518
P A/A or A/G G/G
Number (M: F) 112 (72 : 40) 55 (41 : 14) 0.129
Recipient age (years) 37.0 ± 10.6 33.8 ± 11.3 0.079
Donor age (years) 39.9 ± 14.4 40.1 ± 13.2 0.936
Cadaveric donors 17 (15.3%) 8 (14.5%) 0.925
HLA-mismatch (total number) 2.8 ± 1.1 2.8 ± 1.5 0.762
Calcineurin inhibitors 92% 98% 0.209
Anti IL-2 receptor antibody 24% 20% 0.690
Donor serum creatinine (mg dL
–1) 1.0 ± 0.5 0.9 ± 0.2 0.350
Acute rejection (total) 26.8% 41.8% 0.054
Late acute rejection (after 6 months) 11.6% 25.5% 0.022
Graft survival time (months) 89.1 ± 67.9 85.6 ± 67.3 0.76228 S. W. Kang et al.
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receptor–ligand gene polymorphisms was performed
(Table 4a and b). Recipients with the CCR2-V64I GG
genotype in combination with the MCP-1-2518G/G
genotype had a signiﬁcantly higher risk for acute or late
acute rejection among the combinations (OR  = 4.62,
P = 0.006 or OR = 7.06, P = 0.008). In Table 4, compared
with MCP-1-2518 AA or AG and CCR2-V64I GG, all
other combinations seem associated with acute rejection,
if the arbitrarily conventional signiﬁcance of P < 0.05 is
not rigidly followed.
Statistical analysis of risk factors for graft failure
MCP-1 and CCR2 genotypes were not signiﬁcant risk
factors for allograft failure in the univariate analysis, nor
the combinations of MCP-1 and CCR2 polymorphism.
According to multivariate analysis of risk factors for graft
failure, factors such as donor age, HLA-DR mismatch,
donor serum creatinine, and MCP-1-2518 GG genotype
did not give risks for graft failure. However, younger
recipient group and the occurrence of late acute rejection
gave signiﬁcant risks for allograft failure because respec-
tive odds ratio and P value of recipient age or the occur-
rence of late acute rejection were as follows; odds ratio
for recipient age, 0.911; P = 0.001 or odds ratio for the
occurrence of late acute rejection, 6.48; P = 0.002.
Effect of genotypes on graft survival
A total of 30 grafts (18%) lost function ﬁnally; the mean
graft survival was 88 months. In accordance with a previ-
ous study (Krüger et al., 2002), the G/G genotype was
compared with the combined A/A and A/G genotypes.
The graft survival using the Kaplan–Meier estimation
showed no signiﬁcant difference between the two genetic
groups. In addition, the 64I polymorphism of CCR2 was
not associated with kidney graft survival.
Multivariate graft survival analysis of patients with
acute rejection episodes (n = 53) was performed. Thirty-six
of 53 patients had functioning renal transplant. The
Table 2. Univariate analysis(a) and multivariate logistic regression analysis(b) of variables predicting risk for late acute rejection
(a)
(b)
Variables Rejection N (%) No rejection N (%) OR* 95% C.I.* P
Recipient gender (M:F) 20 : 7 93 : 47  0.437
Recipient age (years) 33.0 ± 12.4 36.5 ± 10.6 < 0.0001
Donor age (years) 42.0 ± 12.3 39.6 ± 14.4 < 0.0001
Number of HLA-mismatch 2.96 ± 1.02 2.80 ± 1.37 < 0.0001
Donor serum creatinine (mg dL
–1) 0.96 ± 0.15 0.99 ± 0.48 < 0.001
Cadaveric donors 4 (14.8%) 21 (15.1%) 0.98 0.32–3.26  0.969
Calcineurin inhibitors 25 (92.6%) 124 (89.2%) 1.51 0.33–7.03  0.598
Anti IL-2 receptor antibody 4 (14.8%) 34 (24.3%) 0.54 0.18–1.68  0.288
GG at MCP-1-2518 14 (52.9%) 41 (29.3%) 2.60 1.13–6.01  0.025




Recipient age (years) 0.99 0.95–1.03 0.565
Donor age (years) 1.02 0.98–1.05 0.382
Number of HLA-mismatch 1.06 0.77–1.47 0.714
Donor serum creatinine (mg dL
–1) 0.90 0.27–3.02 0.858
GG at MCP-1-2518 2.63 1.05–6.58 0.043
a OR; odds ratio, 
b C.I.*; conﬁdence interval.





a G/G 32 14 9 0.139
A/A & A/G 82 17 13
LAR
b G/G 41 10 4 0.024
A/A & A/G 99 12 1
a AR; acute rejection, 
b LAR; late acute rejection.Risk of late acute rejection at MCP-1-2518GG 29
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results showed that the MCP-1-2518G/G recipients with
rejection episodes had poorer graft survival compared
with the A/A or A/G recipients with rejection episodes
after multivariate correction for the risk factors listed in
Table 5. The Cox proportional hazard analysis showed
that the G/G genotype was one of the independent risk
factors for graft failure in patients with acute rejection epi-
sodes, in addition to other risk factors such as donor age,
donor serum creatinine level at pre-operation and the
number of HLA-DR mismatches. The G/G genotype was
associated with a 2.27-fold risk for graft failure in patients
with acute rejection episodes (95% CI; 1.19–4.35;
P = 0.014; Table 5). There was no difference in graft sur-
vival between the G/G and A positive recipients without
rejection episodes (data not shown).
MCP-1 production
The effect of the –2518G-allele on MCP-1 production
after stimulation with the pro-inﬂammatory cytokine IL-
1β was examined. No signiﬁcant differences were noted
between allelic types after IL-1β stimulation (Fig. 1). At
the time of blood collection, the two groups studied for
MCP-1 production did not differ with regard to immuno-
suppressive therapy (P = 0.74 by Fisher’s exact test).
Discussion
Multiple associations have been reported with gene poly-
morphisms of HLA, cytokine, and costimulatory mole-
cules and clinical outcomes of kidney transplantation
(Akalin & Murphy, 2001). Both the CCR2 and the CCR2
ligand, MCP-1, have been shown to be markedly







c P CCR2-V64I MCP-1-2518
G/G AA/AG 8/48 (16.7) 1
G/G G/G 12/25 (48.0) 4.62 1.55–13.75 0.006
GA/AA AA/AG 21/63 (33.3) 2.50 0.99–6.29 0.052
GA/AA G/G 11/30 (36.7) 2.89 1.00–8.37 0.050
a AR; acute rejection, 
b OR; odds ratio, 





c P CCR2-V64I MCP-1-2518
G/G AA/AG 3/48 (6.3) 1
G/G G/G 8/25 (32.0) 7.06 1.67–29.78 0.008
GA/AA AA/AG 9/63 (14.3) 2.50 0.64–9.80 0.188
GA/AA G/G 6/30 (20.0) 3.75 0.86–16.33 0.078
a LAR; late acute rejection, 
b OR; odds ratio, 
c C.I.; conﬁdence interval.
Table 5. Cox proportional hazard model to test the signiﬁcance of 
clinical covariates and genotypes of MCP-1 polymorphism as predictors 




Donor age (years) 1.02 1.000–1.045 0.056
Recipient age (years) 1.01 0.983–1.039 0.449
HLA-DR mismatch 2.46 1.165–5.206 0.019
Donor serum creatinine (mg dL
–1) 2.25 1.022–4.493 0.045
GG genotype at MCP-1-2518 2.27 1.189–4.346 0.014
a OR; odds ratio, 
b C.I.; conﬁdence interval.
Figure 1. MCP-1 levels in the culture supernatant of peripheral blood 
mononuclear cells. Mononuclear cells were isolated from the peripheral 
blood of patients, and cultured with 10 ng mL
−1 IL-1β. The level of 
MCP-1 protein in the culture supernatant was determined by 
sandwich ELISA.30 S. W. Kang et al.
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up-regulated in renal transplant rejection (Grandaliano
et al., 1997; Robertson et al., 2000; Segerer et al., 2001). In
addition, MCP-1 is an important chemoattractant for
monocytes; it is possible that this polymorphism may
affect the migration of monocytes into the rejecting graft.
Few studies, however, have explored the consequences
of genetically determined alterations of receptor–ligand
interactions in the chemokine system.
The results of this study demonstrated an association
between MCP-1 polymorphisms and late acute renal allo-
graft rejection. The proportion of patients with late acute
rejection as well as the number of rejection episodes per
patient was signiﬁcantly higher in patients with the MCP-
1-2518G/G allele. In contrast to previous results (Krüger
et al., 2002) the present study showed no signiﬁcant associ-
ation of allograft failure with the G/G allele of the MCP-
1-2518 polymorphism. Our functional data also showed
that PBMCs isolated from kidney transplant recipients
who carried this allele had a similar production of MCP-
1 to other alleles. However, the functional data may have
been affected by immunosuppressive therapy. The main
purpose in this investigation was to determine whether
there was a difference in graft survival after transplanta-
tion in two genetically different groups among Koreans
with potentially different MCP-1 production. Signiﬁcant
differences were identiﬁed only in patients with rejection
episodes, whereas in patients without rejection episodes
no differences were noted. These results suggest a possible
modifying affect of the MCP-1 polymorphism on the
course of graft rejection, or possibly sensitivity to treatment
affecting graft survival. Because the rejection frequency,
but not the graft survival, was observed to be different in
this study, we suggest that this association may be caused
by a modifying affect of the MCP-1 gene on the initiation
of the rejection reaction but not on the severity.
This graft failure appears to be associated with the
rejection episode and not solely to the presence of the
MCP-1-2518 GG allele; this is supported by the ﬁnding
that there was no difference in graft survival between the
groups of recipients without rejection episodes, and that
there were very few grafts lost among recipients without
acute rejection episodes. These ﬁndings do not support the
G/G allele as an independent risk factor. Although not
clearly apparent from the clinical parameters used to clas-
sify rejection episodes, the G/G recipients had a higher risk
of developing rejection that led to graft loss. However, the
A/A and A/G recipients with rejection episodes were more
likely to develop benign rejection episodes; these episodes
did not lead to loss of the graft during follow-up. The A/
A and A/G recipients were more like the recipients
without rejection episodes. These results provide an
explanation with the genetic background added to earlier
observations that showed that severity, recurrence and
steroid resistance were associated with rejection episodes
and decreased graft survival (Cecka & Terasaki, 1989;
Gulanikar et al., 1992; Vanrenterghem, 1995).
Although there was no difference in the incidence of
rejection among recipients stratiﬁed by the CCR2-V64I
genotype in this study, recipients with the CCR2-V64I GG
genotype in combination with the MCP-1-2518G/G
genotype had a signiﬁcantly higher risk of acute or late
acute rejection among the receptor–ligand combinations
(P = 0.006, P = 0.008, respectively). Therefore, we hypothe-
size that the CCR2 axis may promote the migration of
monocytes into the transplanted kidney; these pairs of
chemokines and their receptors may act sequentially or
simultaneously to facilitate migration and ﬁne positioning
of cells expressing the chemokine receptor. Furthermore,
this association suggests that interactions between the
chemokine receptor polymorphism with the ligand poly-
morphism (gene × gene) may control disease susceptibility
and progression.
Because of the small size of this cohort and its retrospec-
tive nature, this study should be considered preliminary.
Future studies will be needed to conﬁrm these chemokine
receptor–ligand polymorphism associations with trans-
plant rejection incidence as well as to further clarify
their mechanism of action. Precise delineation of how the
chemokine system functions in renal transplantation rejec-
tion may point to new therapeutic targets and prognostic
markers. There was no consideration of the donor geno-
type in this study, although the interaction between cells
in the graft and recipient leukocytes would presumably
have an inﬂuence on rejection. Hoffmann et al. (2004)
demonstrated that donor cytokine polymorphisms can
affect the likelihood of both acute rejection and, perhaps
more strongly, the development of chronic allograft
nephropathy. Future study will be needed to ﬁnd the
affect of donor’s MCP-1 and CCR2 polymorphisms on
transplant outcome.
It is likely that there are different regulatory features
in different ethnic groups. The higher incidence of the G
allele compared to the A allele in Koreans, and a similar
level of MCP-1 production from both alleles, are in con-
trast with previous ﬁndings in European Americans and
Afro Americans (Rovin et al., 1999; Krüger et al., 2002).
Such a discrepancy may be caused by distinct factors
affecting the levels of MCP-1 production in populations
with different genetic backgrounds, possibly as a result of
additional polymorphisms at other genetic loci affecting
the cellular functions of MCP-1. Thus, studies involving
larger and ethnically diverse samples are needed to better
understand functional polymorphisms and to determine
whether they are linked with other genes or interact with
other genes, or are susceptibility markers.
Recipients of renal transplants with the MCP-1-2518G/
G genotype are at increased risk for late acute rejection.
This variant of MCP-1 may provide a novel marker for
late acute rejection in Korean patients.
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